Remove 2019 Remove Development Remove Licensing
article thumbnail

Univ. of Washington rolls out new licensing process to streamline negotiations with spinouts

GeekWire

This week the UW unveiled Husky FAST Start , a new licensing process meant to speed up startup license discussions. universities more control over technology licensing. 1 in 2018 among public universities for the amount of federal money spent annually on research and development. public university. The UW also ranked No.

Licensing 131
article thumbnail

Building new value into cloud licensing

CIO Business Intelligence

Cloud adoption might have the effect of consolidating IT by bringing a host of interactions on to a single platform and shift the cost of running IT from CapEx spending to OpEx, but there is the potential for it to cause licensing “bill shock.” Introducing Cloud Navigator portal. Introducing Cloud Navigator portal.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies

GeekWire

Colleen Delaney, the founder, chief scientific officer, and executive vice president of research and development at Deverra Therapeutics. Founded in 2019, Deverra has an exclusive license from Fred Hutchinson Cancer Research Center for a stem cell expansion and directed-differentiation platform.

article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company, a spin-out from the UW’s Institute for Protein Design , is developing vaccines to resemble naturally occurring viruses. million in 2019 and $18.9 Icosavax Photo). Net losses were $5.3

article thumbnail

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The new funding follows a $51 million round in October 2019. Icosavax Photo). The startup creates computer-designed, virus-like particles that are used in vaccines to trigger immune responses.

article thumbnail

VMware by Broadcom: Product, service and support news

Network World

So far, the $60 billion Broadcom-VMware deal has led to some layoffs , VMware licensing changes, production rationalizations, and shifts to the partner program. Some questioned whether Broadcom would let VMware further develop tools for 5G, software-defined networking (SDN), and other technologies.

Vmware 167
article thumbnail

Seattle Children’s spins out BrainChild Bio, a startup developing therapies for incurable brain cancers

GeekWire

The structure opened in downtown Seattle in 2019. The startup has an exclusive license to use novel CAR T-cell technology developed by Jensen and his team. BrainChild Bio will rent space in the Seattle Children’s building Building Cure.